Harold has served as Tikvah Therapeutics’ President and CEO since its establishment in June, 2006. Under his leadership product licenses have been executed, the business concept and plan were established and the nucleus of the management team has been built. Tikvah Therapeutics, Inc., an Atlanta, GA pharmaceutical enterprise is focused on late-stage development of compounds with strong intellectual property protection and significant market potential. Tikvah Therapeutics, Inc. primary development focus is on the novel application of existing therapeutic entities where clinical proof of concept is already well-established and its commercial focus is in the specialty areas of CNS - psychiatry and neurology. This strategy is designed to minimize the risk of r&d while maximizing the commercial potential of its product assets.

Prior to Tikvah Therapeutics, Harold held various positions of increasing leadership responsibility at Solvay Pharmaceuticals. He most recent held the position of Global Senior Vice President of Solvay Pharmaceuticals, SA reporting directly to the head of the worldwide pharmaceuticals business. This role, including global P&L responsibility, functioned to assure the company effectively managed its regulated activities worldwide. He was a member of the Solvay Pharmaceuticals SA Board of Directors responsible for the worldwide pharmaceutical business, and also remained a member of the Board of Directors of the US pharmaceuticals business.

Shlevin joined Solvay Pharmaceuticals as Senior Vice President of Business Development and Scientific Affairs in August 1998 and served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. from June 2000 to January 2006. He was also a member of the management committee, an officer of the corporation, Chairman of the Board of its independently owned and operated subsidiary Unimed Pharmaceuticals, Inc., and a member of the board of Solvay Draka, a specialty plastic company with interest in medical device applications.

Under Harold’s leadership as CEO, Solvay Pharmaceuticals, Inc. experienced a period of record growth in revenue and profits; these achievements were underpinned by aggressive acquisitions and research and development. Importantly, a long-standing adverse regulatory situation in the USA which blocked product approvals by FDA was resolved without fines or consent decrees. Harold initiated activities and then successfully led the efforts of Solvay Pharmaceuticals, Inc. to apply for a US Federal grant for development and production of new cell-based technologies for influenza vaccine resulting in the Department of Health and Human Services award to Solvay Pharmaceuticals-US for US$298 Million in May, 2006.

Harold has over twenty-five years of diverse healthcare business-related experience, involving virtually every aspect of the pharmaceutical business from research and development through commercial operations. His past industry experience includes leadership roles at G.D. Searle and Co., Ciba-Geigy Corporation, and he was a founder of Ciba Vision Ophthalmics.

After earning a bachelor’s degree from Boston University, Harold earned a master’s and doctorate from University of Rochester Medical School. He holds post-doctoral degrees in pharmacology and physiology from the Mayo Graduate School of Medicine, Mayo Foundation and Mayo Clinic where he also served as Assistant Professor of Pharmacology and Physiology. He served on the Board of Directors of the Pharmaceutical Research and Manufacturers Association of America and the National Pharmaceutical Council and as an Advisor to NanoVici Inc., a nanotechnology oriented, start-up company focused on oncology. He is a member of the American Society of Pharmacology and Experimental Therapeutics, the American Physiological Society, the Biophysical Society, the Drug Information Association, and the Licensing Executives Society. He currently serves on the Board of Directors of the American Foundation for Suicide Prevention, the Board of Advisors of Morehouse School of Medicine, the Board of Directors of Cardiome Pharma Corporation (NASDQ: CRME), Board of Directors for the Georgia Biomedical Partnership and Vice Chair of its Executive Committee.